Wuhan Hiteck Biological Pharma Co.,Ltd

SZSE:300683 Stock Report

Market Cap: CN¥3.2b

Wuhan Hiteck Biological PharmaLtd Past Earnings Performance

Past criteria checks 0/6

Wuhan Hiteck Biological PharmaLtd's earnings have been declining at an average annual rate of -68.5%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 2.3% per year.

Key information

-68.5%

Earnings growth rate

-66.5%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate2.3%
Return on equity-5.7%
Net Margin-21.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Wuhan Hiteck Biological Pharma Co.,Ltd's (SZSE:300683) Shareholders Might Be Looking For Exit

Oct 02
Wuhan Hiteck Biological Pharma Co.,Ltd's (SZSE:300683) Shareholders Might Be Looking For Exit

There's No Escaping Wuhan Hiteck Biological Pharma Co.,Ltd's (SZSE:300683) Muted Revenues Despite A 28% Share Price Rise

Mar 08
There's No Escaping Wuhan Hiteck Biological Pharma Co.,Ltd's (SZSE:300683) Muted Revenues Despite A 28% Share Price Rise

Revenue & Expenses Breakdown

How Wuhan Hiteck Biological PharmaLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:300683 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24615-134263127
30 Jun 24600-132252137
31 Mar 24596-136261133
31 Dec 23602-121238129
30 Sep 23580-59242127
30 Jun 23588-44238115
31 Mar 23661-23235116
01 Jan 23689-14236121
30 Sep 2276928237116
30 Jun 2277639253118
31 Mar 2262321251113
01 Jan 2261528256103
30 Sep 215684245105
30 Jun 21557-1427394
31 Mar 21617-1527095
31 Dec 20524-2525586
30 Sep 20498-1627475
30 Jun 20494328571
31 Mar 205293733962
01 Jan 206206338263
30 Sep 196498642353
30 Jun 1964110341548
31 Mar 1961510038841
31 Dec 185919439830
30 Sep 1858511039126
30 Jun 1863011940533
31 Mar 1871213549124
31 Dec 1775014251924
30 Sep 1782616858017
30 Jun 178271656010
31 Mar 177911616860
31 Dec 167711575590
31 Dec 15679834790
31 Dec 145491104010
31 Dec 13356782450

Quality Earnings: 300683 is currently unprofitable.

Growing Profit Margin: 300683 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 300683 is unprofitable, and losses have increased over the past 5 years at a rate of 68.5% per year.

Accelerating Growth: Unable to compare 300683's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 300683 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.3%).


Return on Equity

High ROE: 300683 has a negative Return on Equity (-5.74%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 19:53
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Wuhan Hiteck Biological Pharma Co.,Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jiaxi XuIndustrial Securities Co. Ltd.